ArticleJournal of biotechnology1999
A recombinant Fab neutralizes dengue virus in vitro.
Article in Journal of biotechnology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Dengue Virus Structural Proteins Are Expressed on the Surface of DENV-Infected Cells and Are a Target for Antibody-Dependent Cellular Phagocytosis.Open forum infectious diseases · 2025Article
- The dengue-specific immune response and antibody identification with machine learning.NPJ vaccines · 2024Article
- Article
- Computer-aided Affinity Enhancement of a Cross-reactive Antibody against Dengue Virus Envelope Domain III.Cell biochemistry and biophysics · 2023Article
- Review
- Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics.Medical microbiology and immunology · 2022Review
- Prospective Artificial Intelligence to Dissect the Dengue Immune Response and Discover Therapeutics.Frontiers in immunology · 2021Review
- Machine Learning Detects Anti-DENV Signatures in Antibody Repertoire Sequences.Frontiers in artificial intelligence · 2021Article
- Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?Pathogens (Basel, Switzerland) · 2020Review
- Structural Vaccinology for Viral Vaccine Design.Frontiers in microbiology · 2019Review
- Molecular basis for dengue virus broad cross-neutralization by humanized monoclonal antibody 513.Scientific reports · 2018Article
- Phage-Displayed Peptides Selected to Bind Envelope Glycoprotein Show Antiviral Activity against Dengue Virus Serotype 2.Advances in virology · 2017Article
- Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.Microbiology and molecular biology reviews : MMBR · 2016Review
- A toggle switch controls the low pH-triggered rearrangement and maturation of the dengue virus envelope proteins.Nature communications · 2014Article
- Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.Immunology · 2014Review
- Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B.Journal of virology · 2014Article
- Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus.Journal of virology · 2013Article
- Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus.Acta pharmacologica Sinica · 2011Article
- In vitro and in vivo studies identify important features of dengue virus pr-E protein interactions.PLoS pathogens · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recombinant Fab that recognizes a neutralizing epitope located in the (296-400) region of protein E of dengue virus was obtained from cloned hybridoma cells secreting the mouse monoclonal antibody (mAb) 4E11. The Fd and light chain antibody genes were amplified by polymerase chain reaction, cloned into the phagemid vector pMad, expressed in bacteria to produce Fab fragments and sequenced. The mAb 4E11, in particular its light chain complementary-determining regions, shared homologies with two other anti-viral mAbs. The affinity of the parental mAb and the cloned Fab to the MalE-E(296-400) fusion protein were shown to be of the same magnitude, i.e. nanomolar. Fab 4E11 neutralization capacity was found between 8 and 4-times or less lower than that of mAb 4E11, depending on serotypes, thus the Fab could have a smaller antiviral activity than the mAb in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.